Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00MYW
|
|||
| Former ID |
DNCL003512
|
|||
| Drug Name |
NS-018
|
|||
| Synonyms |
NS-018; ilginatinib; 1239358-86-1; UNII-56R994WX4L; 56R994WX4L; GTPL7839; SCHEMBL14954406; UQTPDWDAYHAZNT-AWEZNQCLSA-N; NS018; ZINC68245917; HY-19631A; AKOS030526348; DB12784; CS-5358; SB16921; 2,6-Pyridinediamine, N2-((1S)-1-(4-fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N6-2-pyrazinyl-; (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2yl)pyridine-2,6-diamine; (S)-N-(1-(4-Fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N'-(pyrazin-2-yl)pyridine-2,6-diamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Myelofibrosis [ICD-11: 2A20.2; ICD-10: D47.4] | Phase 1/2 | [1], [2], [3] | |
| Company |
Nippon Shinyaku
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C21H20FN7
|
|||
| Canonical SMILES |
CC(C1=CC=C(C=C1)F)NC2=CC(=CC(=N2)NC3=NC=CN=C3)C4=CN(N=C4)C
|
|||
| InChI |
1S/C21H20FN7/c1-14(15-3-5-18(22)6-4-15)26-19-9-16(17-11-25-29(2)13-17)10-20(27-19)28-21-12-23-7-8-24-21/h3-14H,1-2H3,(H2,24,26,27,28)/t14-/m0/s1
|
|||
| InChIKey |
UQTPDWDAYHAZNT-AWEZNQCLSA-N
|
|||
| CAS Number |
CAS 1239358-86-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7839). | |||
| REF 2 | Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis. Blood Cancer J. 2014 Jan 10;4:e174. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.